About Marker Therapeutics, Inc. - Common Stock (MRKR)
Marker Therapeutics Inc is a biopharmaceutical company focused on the development of innovative immunotherapy treatments for cancer. The company specializes in creating personalized T cell therapies designed to harness the body's immune system to target and eliminate tumors. By utilizing a unique approach that enhances T cell functionality, Marker Therapeutics aims to provide more effective treatment options for various types of malignancies, contributing to advancements in oncology and improving patient outcomes through precision medicine. Read More
Marker Therapeutics Inc (NASDAQ: MRKR) announced it is restructuring its clinical programs and strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline.
Marker Therapeutics Inc (NASDAQ: MRKR) released the preliminary results of the first participant treated with MT-601, its multi-tumor associated antigen (multiTAA)-specific T cell product targeting 6 TAAs, in the Phase 1 multicenter
Gainers Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) jumped 76% to $28.13 after the company's once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study in acromegaly.
Gainers Yellow Corporation (NASDAQ: YELL) shares jumped 106% to $1.46. The trucking company ceased operations on Sunday, according to a Wall Street Journal report.
